4D Molecular Therapeutics reports ~$514M cash; President/COO resigns, CEO assumes President role; new director appointed

4D Molecular Therapeutics, Inc.

Fariborz Kamal resigned as President/COO effective Dec 31, 2025; transitions to part-time Chief Technical Advisor.
CEO David Kirn appointed President as of Jan 1, 2026, in addition to CEO role.
Glenn Sblendorio appointed to Board as Class I director effective Jan 5, 2026, serving on Compensation and Science/Technology Committees.
Preliminary cash, cash equivalents and marketable securities ~$514M as of Dec 31, 2025 (unaudited, subject to closing).
Mr. Sblendorio received initial option for 45,000 shares at $7.30 exercise price; annual cash retainer of $40,000 plus committee fees.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.